BIOA logo

BIOAGE LABS INC

BIOANASDAQ
🏆 #3496 by market capUS Equity
$7.14▼ $0.04 (−0.63%)
After hours · at close
🔔
Track BIOA
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 0.6%
7d▼ 15.6%
14d▼ 12.8%
30d▼ 26.2%
ytd▼ 46.0%
1y▲ 30.7%
🏦Market Cap
$269M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
99.4%
High
💵FCF Margin
-850.7%
Thin
⚖️P/S Ratio
25.6x
Expensive
Otter Score
80
Good

Trading Snapshot

Day Range
$7.09 – $7.27
52-Week Range
$5.04 – $25.96
Volume
$3.26B
Avg Volume
$3.31B
Shares Outstanding
37.6M
Next Earnings
Dec 2, 2026

Fundamentals Snapshot

Annual Revenue
$10M
Last Q Revenue
$3M
P/E Ratio
-3.0
P/S Ratio
25.6x
EPS (TTM)
$-2.11
Dividend Yield
0.00%

Why Investors Own BIOA

  • ✓High-growth profile — revenue up +6.7% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 49% gross margin and 8% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

BIOA logo

BIOAGE LABS INC

BIOA
Financial Trends
Revenue (TTM)The total money the company brought in from sales, before subtracting any costs.
$10M▲ +11.9% YoY
Gross Margin (TTM)Of every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
48.5%▲ +1.6% YoY
Operating Income (TTM)Profit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$3M▲ +11.9% YoY
Free Cash Flow (TTM)Cash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$776,625▲ +11.9% YoY
StockOtter · stockotter.space

About BIOAGE LABS INC

BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Good
80/100

Analyst Price Target

ⓘ
Average Target
$7.63
▲ +6.9% Upside
High Target$9.41
Low Target$5.69
Based on 38 analysts

Latest News & Updates

🚀
Bloomberg·2h ago

BIOAGE LABS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Reuters·5h ago

Analysts lift BIOA price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Bloomberg·1d ago

BIOAGE LABS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.